Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Galactomannan C

X
Drug Profile

Galactomannan C

Alternative Names: Carbohydrate polymer; DAVANAT®; GM-CT-01

Latest Information Update: 13 Nov 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pro-Pharmaceuticals
  • Developer Galectin Therapeutics; Icahn School of Medicine at Mount Sinai; Pro-Pharmaceuticals
  • Class Antineoplastics; Mannans; Polymers
  • Mechanism of Action Galectin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Colorectal cancer

Highest Development Phases

  • Discontinued Biliary cancer; Breast cancer; Colorectal cancer; Hepatic fibrosis; Malignant melanoma

Most Recent Events

  • 22 Mar 2019 Discontinued - Phase-I/II for Malignant melanoma (Combination therapy, Metastatic disease) in Belgium (IV)
  • 12 Mar 2019 Cliniques universitaires Saint-Luc- Université Catholique de Louvain terminates a phase I/II trial in Malignant melanoma (Combination therapy, Metastatic disease) in Belgium (NCT01723813)
  • 10 Aug 2017 Discontinued - Phase-II for Biliary cancer (Combination therapy, Late-stage disease, Metastatic disease, Inoperable/Unresectable) in USA (IV)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top